

Cooperation Agreement

on

the collaboration in the joint project entitled

“Montenegro COVID-19 Clinical Associates Initiative - MoCCA”

as a subproject of the joint cooperation

“COVID-19 Response and Recovery Alliance for Montenegro and the Western Balkans –
CORRAL”

Project Number: 1368-1968 (D81968)

between

1. the Federal Republic of Germany, represented by the German Federal Ministry of Health,
represented by the President of the **Robert Koch Institute**, Nordufer 20, 13353 Berlin,
Germany,

- hereinafter referred to as “**RKI**” -

2. the **Charité – Universitätsmedizin Berlin**, represented by the Chairman of the board,
represented by Commercial Director of the Faculty, Charitéplatz 1, 10117 Berlin, Germany;
executing institution: Department of Anaesthesiology, with a focus on Surgical Intensive Care
Medicine, Project Leader: Director of the Clinic, Univ. Prof. Dr. med. C. Spies, Augustenburger
Platz 1, 13353 Berlin, Germany,

- hereinafter referred to as “**Charité**” -

and

3. the **Clinical Centre of Montenegro**, represented by the Director of the KCCG, Ljubljanska
bb, 81000 Podgorica, Montenegro

- hereinafter referred to as “**KCCG**” -

hereinafter, jointly or individually, referred to as **"Party"** or **"Parties"**.

Preamble

WHEREAS, the **Parties** are collaborating within the frame of the Collaboration Agreement effective as of the 31.10.2021 (Collaboration Agreement) concerning the project entitled "Montenegro COVID-19 Clinical Associates Initiative (**MoCCA**)" (hereinafter referred to as the "**Project**") as a subproject to the joint collaboration. "COVID-19 Response and Recovery Alliance for Montenegro and the Western Balkans" (hereinafter referred to as "**CORRAL**").

WHEREAS, **RKI** has received funding from the **BMG** for the implementation of the **Project** (Grant period: 01.11.2021 to 31.12.2022) – file number: ZMI1-2521GHP924. Despite the **Project** being closed, the need has arisen to alter Section 5 of the Collaboration Agreement in order to enable **KCCG** to use the equipment as originally intended by the **Parties**.

NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

Section 1: Subject Matter of the Agreement

This Amendment Agreement regulates the the relationship among the **Parties** with respect to the **Project**, according to the provisions of Section 15.1 of the Cooperation Agreement.

Section 2: Amendments

2.1 Section 5.2 of the Collaboration Agreement shall be amended as follows:

In accordance with its contribution under **Section 2.6 d)**, **Section 6.1** and **Section 6.2**, **RKI** will acquire and transfer all necessary training material and portable medical devices for training (e.g. mobile ultrasound device, portable blood gas analysis devices, telemedical devices) to **KCCG**. The maximum value of material incurred by **RKI** will amount to

- a) **20,000 EURO** in **2021**,
- b) **40,000 EURO** in **2022**

and hence to an overall maximum value of 60,000 EURO within the scope of the **Project**. This includes:

1 unit – InTouch Lite 3, Factory Refurbished - Robot for telemedicine, value excl. VAT: 35,000.00 EUR

2 units – Vscan Extend Dual DICOM, Portable ultrasound device, value excl. VAT: 11,500.00 EUR

with the commercial value amounting to 46,500.00 EURO excluding VAT in total.

2.2 Section 5.4 of the Collaboration Agreement shall be amended as follows:

With the transfer of the materials to **KCCG** according to **Section 5.2**, the ownership of these materials is also transferred to **KCCG**, i.e. the material becomes the property of **KCCG**. As the transfer of material is a contribution within the cooperation between the **Parties**, it naturally comes without any compensation or encumbrance to **KCCG**. The handover of the material shall be made through the Public Procurement Service

INTERAK
KCCG

NEUROLOGIJA
INTEBUNA

Preamble

WHEREAS, **RKI** has already actively participated in research in Montenegro before the COVID-19-pandemic. Additionally, **RKI** has conducted an in-depth intra action review in Montenegro during the pandemic. Based on the results of the intra action review, several needs were identified in the main areas of immediate response to COVID-19, but also to future threats. The good relationship between **RKI** and its long-term cooperation partner **Charité** with the Government of Montenegro with its Institute of Public Health (IPH) and WHO Montenegro provides an excellent opportunity to address these needs first in Montenegro, with the possibility to subsequently expand the subprojects to other states in the Western Balkans, namely Albania, Bosnia and Herzegovina, Kosovo, North Macedonia and Serbia (hereinafter collectively with Montenegro referred to as "WB6"), with Montenegro acting as a hub. The WB6 have been heavily affected by the COVID-19 pandemic.

WHEREAS, **Charité** is one of Germany's most research-intensive medical institutions. **Charité** has been involved in numerous international collaborations. Specifically, the partnership between **RKI** and **Charité** has been in place for many years having jointly implemented projects on a wide range of topics. **Charité** is also a long-term cooperation partner of the **Government of Montenegro** with its IPH and WHO Montenegro

WHEREAS, **KCCG** is a reference institution of the tertiary level of health care for the whole of Montenegro and the secondary level for five South-Eastern Montenegrin municipalities. **KCCG** performs highly specialised diagnoses, treatments, consultations, specialist and sub-specialist examinations. The aim of this exchange between clinicians of **KCCG** and of **Charité** is a more unified and stringent approach to the treatment of COVID-19 patients at **KCCG** and throughout the whole country of Montenegro by forming a national network and transferring the knowledge.

WHEREAS, **RKI** is the German national public health institute, responsible for the detection, prevention and control of diseases, in particular infectious diseases. It is a Federal Institute within the portfolio of the German Federal Ministry of Health (Bundesministerium für Gesundheit, hereinafter referred to as "**BMG**"). **RKI**'s stated goal is to assume even greater responsibility for international and global health issues and to thereby make an important contribution to health protection not only in Germany, but also worldwide.

WHEREAS, the Parties intend to implement the joint collaboration "COVID-19 Response and Recovery Alliance for Montenegro and the Western Balkans" (hereinafter referred to as "**CORRAL**"). **CORRAL** aims to support current response activities by establishing capacities that will likewise increase resilience to future threats, in particular, by means of implementing the four subprojects:

1. "Montenegro COVID-19 Clinical Associates Initiative (**MoCCA**)",
2. "Western Balkan Laboratory Network (**WALTON**)",
3. "MONTENEGRO VIRTUAL Emergency Operation Center (**MoVE**)" and
4. "Field Epidemiology Training Programme (**FETP-WB**)"

Moreover, **CORRAL** aims to establish a strong bilateral partnership with Montenegro as a future hub for the other WB6 countries. The Parties plan to sign a letter of intent regarding the overall collaboration **CORRAL** in good time.

WHEREAS, the first sub-project to be established, namely **MoCCA** (hereinafter referred to as the "**Project**"), is the main objective of this agreement and aims to support a unified approach to the treatment of patients with COVID-19 and other severe diseases in **KCCG** by establishing of an international network of health care experts, including **KCCG**, **Charité** and other partners in Germany. It reflects the outcomes of two consecutive visits to Montenegro, and in-depths discussions between colleagues from **KCCG** and experts from the **Charité** and **RKI**. The **Project** will address clinical experts in the field of COVID-19 treatment, as well as intensive care unit (ICU) experts in general. The participating clinicians of **KCCG** and **Charité** aim to

build a network (herein referred to as the "**MoCCA Network**"), enabling a mutual exchange of experience and knowledge between **KCCG** and **Charité**. Special focus will be given to the rational use of antibiotics, anticoagulants and anti-inflammatory drugs. Furthermore, the Project aims to support the local development of guidelines and teaching material, the establishment of local networks and the use of digital tools for monitoring.

WHEREAS, the **Project** shall be carried out in cooperation by the **Parties** in accordance with the Grant Application. The Grant Application is attached as *Annex I* to this Agreement. According to *Annex I*, the **Project** is composed of six Modules identified by a multidisciplinary expert collaboration between **RKI** the **Parties**:

- Module 1: Kick-off workshop in Podgorica
- Module 2: Training of one cohort of selected clinicians from Montenegro at **Charité** clinics in Berlin (2021)
- Module 3: Training of two cohorts of selected clinicians from Montenegro at **Charité** clinics in Berlin (2022)
- Module 4: At least two webinars for clinicians in Montenegro (2021/2022)
- Module 5: Evaluation of the **Project**
- Module 6: Workshop with participation from the WB6 to explore the way forward and additional approaches, such as telemedicine.

As regards the detailed conduction of each Module by the respective **Parties**, we refer to the Grant application in *Annex I* and the Budget Plan attached as *Annex II* to this agreement.

WHEREAS, **RKI's** Centre for International Health Protection (**ZIG**) aims to contribute to the international effort against SARS-CoV-2 as part of its strategy to strengthen health sustainably in international contexts. The **Project** is *i.a.* intended to strengthen health systems through international collaboration. It shall establish interprofessional, cross-national training with shadowing in respiratory and positioning therapy and initiate interdisciplinary, cross-hospital exchange between intensive care specialists, infectiologists and critical care nurses from Montenegro and Germany in order to augment capacities in critical care medicine for COVID-19 as well as for long-term capacity building.

WHEREAS, **RKI** has received funding from the **BMG** for the implementation of the **Project** (Grant period: 01.11.2021 to 31.12.2021) – file number: ZMI1-2521GHP924 - (hereinafter referred to as "**Grant**").

NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

Section 1: Subject Matter of the Agreement

This Agreement is intended to specify the relationship among the **Parties** with respect to the **Project**, in particular concerning the respective responsibilities of the **Parties**, the management of the **Project** and the rights and obligations of the **Parties**.

Section 2: Contributions and Responsibilities of Parties

2.1 Each **Party** undertakes to take part in the efficient implementation of the **Project**, and to cooperate, perform and fulfil, promptly and on time, all its obligations under this Agreement including the Annexes thereto as may be reasonably required from it and in a manner of good faith.

2.2 Each **Party** undertakes to notify promptly any significant information, fact, problem or delay likely to affect the **Project**. The respective **Parties** will exchange and share among themselves the contents of the Grant allocation decisions, task descriptions, **Project** schedules as well as all data and information necessary to carry out the **Project**.

2.3 A **Party** that enters into a subcontract or otherwise involves third parties in the **Project** remains responsible for carrying out its relevant part of the **Project** and for such third party's compliance with the provisions of this Agreement. It has to ensure that the involvement of third parties does not affect the rights and obligations of the other **Parties** under this Agreement. **Section 14.2** shall remain unaffected.

2.4 **Charité** will

- a) organise and conduct a kick-off workshop in Podgorica in 2021 jointly with all **Parties**,
- b) provide criteria for the common accountability framework jointly with **KCCG**,
- c) nominate suitable cohort candidates from **KCCGs** medical and nursing staff to participate in the training in Berlin jointly with **KCCG**, who will be chosen by the Steering Committee (see hereto **Section 4.2**),
- d) organise one training for a first cohort from **KCCGs** medical and nursing staff in 2021 and two more trainings in 2022 jointly with all **Parties**,
- e) conduct said training for the three cohorts from **KCCGs** medical and nursing staff at the **Charité** clinics in Berlin
- f) organise and conduct at least two webinar services of clinicians in Montenegro during the duration of the **Project**,
- g) hold a workshop with participation from all WB6 countries to explore and define next steps and additional approaches jointly with all **Parties**,
- h) prepare and conduct clinical case conferences jointly with **KCCG**,
- i) support the **MoCCA Network** in developing training materials and training guidelines,

- j) participate in the steering committee for the **Project**,
- k) conduct the evaluation exercises according to the accountability framework jointly with all **Parties**,
- l) contribute to the dissemination of results jointly with all **Parties** and
- m) assist, if required by **RKI**, in preparing manuscripts for progress or study reports for **BMG**, and participate in the preparation of other publications according to **Section 11**.

2.5 **KCCG** will

- a) organise and conduct a kick-off workshop in Podgorica in 2021 jointly with all **Parties**,
- b) provide criteria for the common accountability framework jointly with **Charité**,
- c) nominate suitable cohort candidates from **KCCGs** medical and nursing staff to participate in the training in Berlin jointly with **Charité**, who will be chosen by the Steering Committee (see hereto **Section 4.2**),
- d) organise one training for a first cohort from **KCCGs** medical and nursing staff in 2021 and two more trainings in 2022 jointly with all **Parties**,
- e) participate in the workshops, trainings, webinars and case conferences conducted by **Charité**,
- f) hold a workshop with participation from all WB6 countries to explore and define next steps and additional approaches jointly with all **Parties**,
- g) develop training materials and training guidelines within the **MoCCA Network**,
- h) participate in the steering committee for the **Project**,
- i) conduct the evaluation exercises according to the accountability framework jointly with all **Parties**,
- j) contribute to the dissemination of results jointly with all **Parties** and
- k) assist, if required by **RKI**, in preparing manuscripts for progress or study reports for **BMG** and participate in the preparation of other publications according to **Section 11**.

2.6 **RKI** will

- a) organise and conduct a kick-off workshop in Podgorica in 2021 jointly with all **Parties**,
- b) organise one training for a first cohort from **KCCGs** medical and nursing staff in 2021 and two more trainings in 2022 jointly with all **Parties**,

- c) conduct the evaluation exercises according to the accountability framework jointly with all **Parties**,
- d) procure and transfer training material (see hereto **Section 5**) to the corresponding sites as well as facilitate the traveling of the cohorts to the training sites in Berlin financially
- e) financially support the **Project** by the means of the **Grant** (see hereto **Section 6**) and in accordance with the Budget Plan (*Annex II*)
- f) jointly with all **Parties** contribute to the dissemination of results and
- g) prepare manuscripts a progress and a study report for **BMG** and participate in the preparation of other publications according to **Section 11**.

2.7 **Charité** and **KCCG** are obliged to submit a final scientific report about their respective results and contributions within the scope of the **Project** to **RKI**. The final scientific report must be submitted until the **30th of April 2022**.

Section 3: Implementation of research, transfer of personal data

3.1 Any research under this **Project** shall be carried out in accordance with the applicable laws and directives and/or regulations (for example genetic engineering, animal protection, radiation protection, etc.) good laboratory practices, guidance notes and procedures for each country. Where applicable, applications for the registrations, permits or ethical approvals required are to be made and collected in time

3.2 The **Parties** hereby agree that personal data will only be transferred and processed after the conclusion of appropriate additional contractual agreements and in accordance with all laws, regulations, good laboratory practices, guidance notes and procedures including, but not limited to, the Declaration of Helsinki applicable in Germany.

Section 4: Coordination, Steering Committee, project managers

4.1 Overall **Project** coordination is ensured by **RKI**. In particular, **RKI** has the task of coordinating the work of the individual **Parties** both in terms of technical implementation, e.g. travelling of the **KCCG** cohorts, and time. If deviations from the overall work schedule and timetable occur, it will draw the attention to the **Parties** as early as possible and propose measures to overcome the difficulties encountered. If deadlines cannot be met by one **Party**, the other **Parties** must be notified immediately.

4.2 Representatives of **KCCG** and **Charité** will form the Steering Committee. The Steering Committee is responsible for the content of teaching and other content related organisation of Webinars, Workshops and Trainings under this Project. **KCCG** and **Charité** shall arrange regular meetings of the Steering Committee to ensure proactive continuous exchange throughout the **Project**. The frequency of such meetings shall be mutually agreed by **KCCG** and **Charité**.

4.3 Throughout the **Project** communication process, all **Parties** shall provide a response to project emails exchanges in due time, if required. For emails with urgent requests and if required, all **Parties** shall provide a prompt response without undue delay.

4.4 Each **Party** appoints a project manager. The project managers are responsible for the proper execution of the work. The **Parties'** respective project managers' contact information are as follows:

Charité:

Project manager: Prof. Dr. Claudia Spies

Email: Claudia.spies@charite.de

Tel.: +49 (0)172 3940990

KCCG:

Project manager: Dr. Ljiljana Radulovic

Email: ljiljana.radulovic@kccg.me

Tel.: +382 20 243 726 (office) / mob: +382 69 091 714 (mobile)

RKI:

Project manager: Dr Andreas Jansen and R. Sabrina Weiß

Email: JansenA@rki.de; WeissS@rki.de

Tel: +49 30 18754 3459

4.5 If, during the term of this Agreement, one **Party's** project manager resigns or, for another reason, leaves the project management and the concerned **Party** has no other project manager who is already appointed, a similarly qualified employee shall be appointed as successor for the execution of the research work after notification to the other **Parties**.

Section 5: Travel expenses and Material

5.1 In accordance with its contribution under **Section 2.6 d)**, **Section 6.1** and **Section 6.2**, **RKI** will acquire and transfer all necessary tickets for the travel of the **KCCG** training cohorts to Berlin in 2021 and 2022. The maximum value of tickets incurred by **RKI** will amount to

a) **15,000 EURO** in **2021**,

b) **35,000 EURO** in **2022**

and hence to an overall maximum value of 50,000 EURO within the scope of the **Project**.

5.2 In accordance with its contribution under **Section 2.6 d)**, **Section 6.1** and **Section 6.2**, **RKI** will acquire and transfer all necessary training material and portable medial devices for training (e.g. mobile ultrasound device, portable blood gas analysis devices, telemedical devices) to **KCCG**. The maximum value of material incurred by **RKI** will amount to

a) **20,000 EURO** in **2021**,

b) **40,000 EURO** in **2022**

and hence to an overall maximum value of 60,000 EURO within the scope of the **Project**.

5.3 **KCCG** will support **RKI** by identification of specific needs and facilitation of procurement and shipping, e.g. necessary customs clearance at country level.

5.4 With the transfer of the materials to **KCCG** according to **Section 5.1**, the ownership of these materials is also transferred to **KCCG**, respectively.

5.5 **KCCG** ensure to use the laboratory materials according to **Section 5** only for the purposes of this Agreement and in compliance with the applicable national and international laws.

Section 6: Financial regulations

6.1 **RKI** has been allocated a Grant by **BMG**. This funding is destined to cover the expenses incurred by the **Parties** during the **Project**. Hence, **RKI** will in accordance with the Budget Plan (*Annex II*) carry the costs of the **Project** for

- a) travel of training cohorts to Berlin (see hereto **Section 5**),
- b) material for the implementation of the **Project**, including training material and support tools in **KCCG** as well as (see hereto **Section 5**)
- c) personnel in Germany for the implementation of the **Project** as well as the overall **Project** coordination.

6.2 As regards those costs, **RKI** will either make an upfront payment (see hereto **Section 6.8**), reimburse **Charité** for those costs under the following conditions:

- a) The costs are actually incurred by said **Parties** during the term of the Agreement and must be necessary for the implementation of the **Project**,
- b) they must be identifiable and verifiable, in particular recorded in the accounts of said **Parties** in accordance with the respective applicable accounting standards,
- c) they must be reasonable and cost-efficient,
- d) they must comply with the applicable national laws on taxes, labour and social security and

6.3 Personnel costs will only be covered in an upfront payment (see hereto **Section 6.8**) or reimbursed by **RKI** if the following conditions are met in addition to those stated in **Section 6.2**:

- a) personnel costs have to be related to personnel employed by **Charité** for the implementation of the **Project**,
- b) personnel costs must be limited to salaries, social security contributions, taxes and other costs arising directly from national and international laws or the employment contract and
- c) **Charité** declares that the costs are in accordance with its usual remuneration practices and are paid in a consistent manner whenever the same kind of work or experience is required regardless of the respective source of funding.

6.4 the maximum amount of the **BMG Grant** transferred to **Charité** will amount to

- a) **15,810.00 EURO** in **2021**
- b) **94,864.00 EURO** in **2022**

and hence to an overall maximum value of 110,674.00 EURO for the duration of the **Project**.

6.5 Reimbursement and/or direct payment to a product/service company requires

- a) the submission of records and other supporting documents to prove the costs declared such as contracts, invoices and accounting records and
- b) written confirmation by an authorised representative of the respective **Party** of the fact that the costs claimed meet the requirements laid out in **Section 6.1**.

All documents submitted to **RKI** must indicate the **Project number: 1368-1968 (D81968)**

6.6 All documents mentioned under **Section 6.5** concerning costs incurred until the **10.12.2021** must be received by **RKI** by **10.12.2021 at the latest**. Documents received subsequently will not be considered and the respective costs not be reimbursed. For the reimbursement of costs incurring in the period between the **11.12.2021** and the **31.12.2021**, the respective **Party** has to submit a statement of anticipated expenditures showing the expected costs for this period by **10.12.2021**. After the costs have actually incurred, the respective **Party** has to submit the respective confirmatory documents immediately, but no later than **15.01.2022**. If these costs turn out to be higher than initially expected, there is no entitlement to additional payment. If the costs turn out to be lower, the repayment of the overpaid amounts must be reported to **RKI** by **15.01.2022** and initiated by **31.01.2022 at the latest**. However, **RKI** asks **Charité** to provide all documents under this **Section 6.5** as early as possible, **preferably until the 30.11.2021**.

6.7 All documents mentioned under **Section 6.5** concerning costs incurred until the **15.10.2022** must be received by **RKI** by **31.10.2022 at the latest**. Documents received subsequently will not be considered and the respective costs not be reimbursed. For the reimbursement of costs incurring in the period between the **16.10.2022** and the **31.12.2022**, the respective **Party** has to submit a statement of anticipated expenditures showing the expected costs for this period by **15.10.2022**. After the costs have actually incurred, the respective **Party** has to submit the respective confirmatory documents immediately, but no later than **15.01.2023**. If these costs turn out to be higher than initially expected, there is no entitlement to additional payment. If the costs turn out to be lower, the repayment of the overpaid amounts must be reported to **RKI** by **15.01.2023** and initiated by **31.01.2023 at the latest**.

6.8 As an exception to **Section 6.6** to **Section 6.7**, **RKI** may change the therein by unilateral declaration to **Charité** if necessary according to the requirements of the Grant allocation order by **BMG**. In addition, the **Parties** agree to further amend the Agreement by mutual agreement, if this is necessary according to the requirements of the allocation order by **BMG**.

6.9 **Charité** may request an advance payment up to a maximum of **80%** of funds approved per calendar year in accordance with the Budget Plan (*Annex II*). The bank account details must be stated in each case.

6.10 The payments are made by transfer to a respective account to be designated by **Charité** in EURO.

6.11 **RKI** may refuse to make payments to a **Party** as long as that **Party** has failed to fulfil its obligations according to this Agreement.

Section 7: Right to audit and duty to inform

7.1 **RKI, BMG**, and/or the German Federal Court of Auditors (Bundesrechnungshof) may at any time perform an audit, or arrange for an auditor to perform an audit of the status and results of the implementation of **Project**, and the appropriate application of the **Grant** funding. The other **Parties** must keep the necessary documents ready for the audit, present these upon demand with reasonable advance notice from **RKI**, and remain available to provide further information as requested.

7.2 If it is shown, e.g., revealed by an audit according to **Section 7.1**, that a payment of **RKI** was not in accordance with the provisions of this Agreement, **RKI** shall be entitled to a refund from the respective **Party**. Further, if a **Party** has committed fraud or is in serious breach of its obligations under this Agreement or has made false declarations in connection with the reimbursement of costs, it is obligated to immediately repay the full amount of the funding received by **RKI** in connection with the implementation of the **Project** under this Agreement.

7.3 Each **Party** must promptly notify the other **Party** of all material changes of relevance to the **Project**, and must fulfil its duties to provide information.

Section 8: Pre-Existing Intellectual property

8.1 Each **Party** is and remains the owner of its intellectual property (protected and unprotected) existing as of the Effective Date of this Agreement as set out in **Section 13.1** and intellectual property obtained by a **Party** outside the scope of this **Project** (hereinafter referred to as **Pre-Existing Intellectual Property**).

8.2 Each **Party** grants the other **Party** a free, non-exclusive, non-sublicensable and non-transferable right of use for the duration of the **Project** on its **Pre-Existing Intellectual Property**, insofar as this is necessary for the implementation of this **Project** and/or if needed for the non-commercial use of any **Work Results** (as defined in **Section 9**) provided that no third-party rights prevent this. Such right to use granted here does not, in particular, entitle to modify or change any inventions of the **Parties** that may result from the **Project** and does not affect **Pre-Existing Intellectual Property** rights contributed by any **Party**.

8.3 To the extent that **Pre-Existing Intellectual Property** of a **Party** is required for the commercial exploitation of any **Work Results** (as defined in **Section 9**) or for purposes outside the scope of or after the end of the collaborative **Project**, the **Party** may grant the other **Party** requiring such **Pre-Existing Intellectual Property**, a non-exclusive right of use to customary market conditions to the extent that no third-party rights conflict.

8.4 Insofar as conflicting rights of third parties become known, each **Party** shall inform the other **Party** immediately.

8.5 The Parties ensure that in accordance with **Section 2.3** regulations in **Sections 8.1 to 8.4** apply accordingly to **Pre-Existing Intellectual Property** contributed to the **Project** under the objectives of this Agreement by third parties.

Section 9: Work Results

9.1 **Work Results** are any outcome, including reports and documents prepared, obtained by the **Parties** in carrying out their tasks under the **Project** (e.g., know-how, data, inventions, results protected by copyright, software etc.).

9.2 **Work Results** (patentable and non-patentable) developed within the scope of the **Project** shall belong to the **Party** that has originated them. If the **Parties** have jointly originated them ("**Joint Owners**") and it is not possible to establish the respective contribution of each **Party** or to separate them for the purpose of applying for, obtaining or maintaining their protection, the **Joint Owners** must agree in writing on the allocation and terms of exercise of their joint ownership.

Section 10: Rights of use in relation to Work Results

10.1 Each **Party** shall be granted a free, non-exclusive, non-transferable and non-sublicensable right to use any **Work Results** created by both **Parties** and/or by the other **Party** for the duration and purpose of the **Project**.

10.2 In addition, after the termination of the **Project**, each **Party** shall be granted a free, non-exclusive, non-transferable, non-sublicensable and royalty-free right to use any **Work Results** created by the **Parties** and/or created by another **Party** for non-commercial purposes in scientific research, public service and training.

10.3 If any **Work Results** belonging to another **Party** are required for commercial exploitation or other purposes not covered under **Section 10.1 and 10.2** by a **Party**, this **Party** may, upon request, obtain a non-exclusive right of use from the **Party** owning such **Work Results** under customary market conditions. Details shall be determined by the respective **Parties** in a separate agreement.

10.4 In accordance with the regulations of **BMG** on the allocation of the **Grant**, the **Parties** hereby grant **BMG** and its subordinate authorities a non-exclusive, non-transferable, royalty-free right of use to all types of use for the **Work Results** and developments of the **Project**. The right of use is unlimited in respect of place, time and content.

Section 11: Publications

11.1 **BMG** is entitled to publish a short report on the **Project** on the internet. This report will be produced by **RKI** with mandatory support of the other **Parties**.

11.2 The **Parties** are entitled to publish a short description of the **Project**, its scope of work and the distributions of contributions between collaborating parties as part of their regular public relations work with prior consent of **RKI**.

11.3 The **Parties** intend to publish the research results obtained within the **Project** jointly in a manuscript drafted by **RKI** with the support of the other **Parties**.

11.4 Other publications, not mentioned in **Sections 11.1 to 11.3**, containing confidential information or **Work Results** of another **Party** or to which another **Party** has contributed, require the prior written consent of the other **Party**. No **Party** may unreasonably withhold its consent, if necessary subject to changes or deletions. If it does not object to a publication submitted to it (original text) within four weeks of receipt of the complete documents to be published, its consent shall be deemed to have been granted. The **Parties** agree that any publication shall be made in accordance with the protection of intellectual property rights, confidentiality obligations and the general principles of authorship like the "uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication" of the International Committee of Medical Journal Editors (<http://www.icmje.org>).

11.5 Each **Party** may publish its own **Work Results** in peer-reviewed journals with prior written approval of the publication by **RKI**.

11.6 In all publications or presentations, the **Parties** will point out that the **Project** has been a cooperation between **Charité, KCCG** and **RKI**. Further, in all publications or presentations, the **Parties** are required to expressly point out that financial support for the **Project** is provided by the Federal Republic of Germany. Therefore, any publication related to the **Project** must include the logos and texts available on the Internet at

<https://styleguide.bundesregierung.de/sg-de/basiselemente/bildwortmarke/bildwortmarke-mit-foerderzusatz>

using the following login details:

Username (Benutzername): cd_downloads_foerdermarke

Password (Passwort): CDM05bpa

In addition, all publications on the Internet should be barrier-free, e.g. using the format PDF/UA (<https://www.access-for-all.ch/ch/barrierefreiheit/barrierefreie-pdf-dokumente/pdf-ua.html>).

Section 12: Confidentiality

12.1 Each **Party** shall keep confidential all information, notices, documents and experiences of the other **Parties** which are known to it on the basis of this Agreement and which are identified as confidential or by the nature of which the receiving **Party** knew or should have reasonably considered it to be confidential ("**Confidential Information**"), for the duration of this Agreement and for 5 (five) years beyond the duration of this Agreement. **Confidential Information** of another **Party/** other **Parties** shall be disclosed to third parties only with prior consent by the **Party/** the **Parties** concerned and only to the extent necessary to fulfil this Agreement. Such third party shall be obliged, in writing, to maintain confidentiality of the **Confidential Information** in accordance with this **Section 12**. Each **Party** shall ensure that

the companies affiliated with it comply with the obligations of confidentiality under this Agreement and it shall be responsible for the unauthorized use or disclosure of **Confidential Information** by such affiliated companies.

12.2 The obligation of confidentiality shall not apply insofar as this **Confidential Information** demonstrably

- a) was already known to the receiving **Party** prior to receipt of the **Confidential Information**;
- b) was generally known before notification or became generally known on the basis of a notification without fault on the part of the receiving **Party**;
- c) has been disclosed or made accessible by a third party with no obligation to maintain confidentiality; or
- d) has to be compulsorily disclosed on the basis of law, regulations or official instructions provided that any involved **Party** is informed of this obligation in good time prior to disclosure and utilizes reasonable means of legal protection and procedural safeguarding of the confidentiality.

The **Party** who refers to one of the exemptions must provide the appropriate proof.

Section 13: Duration, termination

13.1 This Agreement enters into force retroactively as of 31.10.2021 and will end after **BMG** accepts the final report. The duration of the **Project** is from 01.11.2021 (Effective Date) until 31.12.2022. Any extension of the **Project** term by **BMG** shall automatically extend this Agreement if not agreed otherwise by the **Parties**.

13.2 Each **Party's** right to immediate termination for good cause remains unaffected.

13.3 In the event that a **Party** commits a breach or default of any of the terms or conditions of this Agreement, and fails to remedy such default or breach (if capable of remedy) within 14 (fourteen) days from the date of a written notice of such breach or default from **RKI**, **RKI** may – in consultation with the other non-defaulting **Parties** decide to terminate the **Project** participation of the defaulting **Party** by written notice to the defaulting **Party**. A breach or default is deemed to exist, in particular, if a material term or condition of the Agreement, in particular but not limited to the obligations under **Section 2**, is breached.

13.4 The termination of this Agreement shall not affect the rights and obligations of any **Party** accrued as of the termination date of the Agreement. The provisions of **Sections 7 to 12** shall remain in force after the termination of this Agreement.

Section 14: Liability

14.1 The **Parties** shall carry out the work undertaken by them within the framework of the **Project** properly and to the best of their knowledge, considering the state of the art in science and technology. The **Parties** do not guarantee that the results of their **Work Results** are free of third party-rights and that specific results will be achieved. However, as soon as a **Party**

becomes aware of such third party-rights, it shall inform the other **Parties** thereof and take appropriate corrective action.

14.2 No **Party** shall be in violation of this Agreement for delays incurred due to force majeure and/or actions on the side of third parties if the **Party** can show that adequate steps according to **Section 2.1** had been taken in a timely manner and the relevant information has been passed promptly according to **Section 2.2** on to the other **Parties**.

14.3 Within the framework of the cooperation, the **Parties** will carry out the transmission of information with the care customary in their own affairs. The **Parties** shall not be liable for the correctness and completeness of the information provided by them within the framework of this Agreement or for any damage whatsoever resulting from the use of this information, either during the term of the cooperation or after the end of the contract.

14.4 Otherwise, the **Parties**, their legal representatives and vicarious agents shall only be liable to each other for intent and gross negligence. In the event of gross negligence, liability shall be limited to the amount of the respective contribution.

14.5 The foregoing limitations or exclusions of liability shall not apply in the event of injury to life, limb or health.

Section 15: Form and contract hierarchy

15.1 Amendments and additions to this Agreement require the written agreement of all **Parties**. Signatures sent via email-fax shall also bind the **Parties** to this Agreement. This requirement can also only be amended in written form by the **Parties**.

15.2 Should the provisions of this Agreement contradict the provisions of *Annex I* in whole or in part, the provisions of this Agreement shall prevail. As an exception to this, the budget plan in *Annex II* shall prevail the budget specifications in *Annex I* and the specifications of this agreement if any contradictions arise.

Section 16: Applicable law and jurisdiction

16.1 This Agreement shall be governed by and construed under the laws of Germany excluding the conflict-of-law rules of private international law. For the sake of clarification, for all contractual relations that **Charité** or **KCCG** enters into with third parties for the implementation of this Agreement, e.g., but not limited to contracting of contractors, procurement of materials and equipment, this contractual provision does not apply.

16.2 In case of any dispute arising out or in relation to this Agreement the reprehensive bodies of the **Parties** will intervene to settle matters amicably. Lastly, the **Parties** can resort to the competent courts of Berlin (Germany) for settlements.

Section 17: Severability clause

Should individual provisions of this Agreement be invalid, the validity of the remaining provisions shall not be affected thereby. Instead of the ineffective provision, a regulation shall

be applicable that comes closest to what the **Parties** would have wanted or had wanted if the invalidity of the provision had been known to them. The same applies to any potential regulatory gaps in the agreement.

Section 18: No waiver

No waiver by a **Party** of any breach or default by any other **Party** shall operate as a waiver of any succeeding breach or other default or breach by such other **Party**. A **Party's** failure or delay in exercising any right or remedy provided under this Agreement or by law shall not constitute a waiver by that **Party** of that or other right power or remedy, nor shall it preclude or restrict such **Party** from any further exercise of that or other right or remedy.

Section 19: No assignment


Except as expressly provided in this Agreement, no **Party** may assign or transfer this Agreement as a whole, or any of its rights or obligations under it, without first obtaining the written consent of the other **Parties**; such consent may not to be unreasonably withheld or delayed.

Annexes:

- Annex I: Grant Application
- Annex II: Budget Plan

For KCCG

Place, date: Podgorica, 08.12.2021

A handwritten signature in black ink, appearing to read 'Ljiljana Radulović', written over a horizontal line.

Dr Ljiljana Radulović,

Director of Clinical Centre of Montenegro

For Charité

Berlin, date:


i.V.

Anne Großkopff

Commercial Director of the Faculty, Charité University Medicine Berlin (Kaufmännische Direktorin der Fakultät, Charité Universitätsmedizin Berlin)

Digital unterschrieben
von Dr. Katharina
Flemming
Datum: 2021.12.08
16:11:39 +01'00'

**Dr. Katharina
Flemming**

i.O. 
UNIVERSITÄTSMEDIZIN BERLIN
Charité
Geschäftsbereich
Charitéplatz 1 | D-10117



For Charité: read and acknowledged

Berlin, date:

Univ. Prof. Dr. med. C. Spies

Director of the Clinic for Anesthesiology with a focus on Surgical Intensive Care Medicine, Charité University Medicine Berlin (Direktorin der Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Charité Universitätsmedizin Berlin)

08.12.21

CHARITÉ
UNIVERSITÄTSMEDIZIN BERLIN
Klinik für Anästhesiologie m.S. operative
Intensivmedizin CCM / CVK
Direktorin: Univ.-Prof. Dr. med. Claudia Spies
Campus Charité Mitte
Charitéplatz 1 | D-10117 Berlin
Telefon: +49(0)30 450 - 531 012 / 052
Telefax: +49(0)30 450 - 531 911
Campus Virchow-Klinikum
Augustenburger Platz 1 | D- 13353 Berlin
Telefon: +49(0)30 450 - 551 - 102/002/022
Telefax: +49(0)30 450 - 551 909

For RKI

Berlin, date: 09.12.2021

p.p.
Prof. Dr Lothar H. Wieler

President of the Robert Koch Institute

Prof. Dr. Lars Schaade
Vice President
Robert Koch Institute
Nordufer 20
D-13353 Berlin
GERMANY

ROBERT KOCH INSTITUTE



Centre for International Health Protection
ZIGi - Information Centre for International
Health Protection

Robert Koch-Institut | Nordufer 20 | 13353 Berlin

Klinički Centar Crne Gore (KCCG)
Ljubljanska bb
81000 Podgorica
Montenegro

Contact person:
Dr. Ljiljana Radulović, Director KCCG
ljiljana.radulovic@kccg.me
+382 20 243 726

PROFORMA INVOICE

28 January 2022

The listed device is sent on behalf of the Robert Koch Institute (German Federal Institute for Infectious and Non-communicable Diseases), Berlin, Germany, to the Clinical Centre of Montenegro (Klinički Centar Crne Gore) in Podgorica, Montenegro. The device will be used for information exchange between hospitals in the process of intensive care treatment of patients with in the actual outbreak situation of COVID-19. These items are non-infectious, non-toxic, non-explosive, and not harmful to the environment or human health and are only used for medical treatment purposes.

Robert Koch Institute
zentrale@rki.de
Tel: +49 (0)30 1871-340
Fax: +49 (0)30 1871-4242
www.rki.de

Processing by:
Dr. Andreas Jansen

Extension Cause
E-Mail: jansen@bvg.gv.at

Address:
Nordufer 20
13353 Berlin
Federal Republic of Germany

All items are listed as follows:


Product description	Unit price (EUR)	Quantity	Total price (EUR)	HS code
InTouch Lite 3, Factory Refurbished / 20-20310	14,016.84	1	14,016.84	9517.18.0000

Manufactured by: InTouch Technologies Inc.

The total net value (for customs purpose only) is: 14,016.84 €
The total gross weight is 274 kg.

The device concerned is not intended for sale and provided free of charge to the Clinical Centre of Montenegro, Podgorica. All materials are humanitarian goods.

FOR CUSTOMS PURPOSES ONLY.


Dr. Andreas Jansen
Head of the Unit ZIG1

Ракочевин Сања
20244



is a legal institution
within the portfolio of the Federal
Ministry of Health

JEDINSTVENA CARINSKA ISPRAVA

I DEKLARACIJA

Carinska isprava Terminal Podgorica
35025 /
Reg Br: 10167

PRIMJELAK ZA UVOZNIK	2 Pošiljalac/Izvoznik ROBERT KOCH INSTITUTE NORDUFER 20, 13353 BERLIN NJEMAČKA/276	M.B.
	3 Pribor KLINIČKI CENTAR CRNE GORE LJUBLJANSKA BB, 81000 Podgorica	02016366
	4 Broj izvoza BOSNE I HERCEGOVINE LJUBLJANSKA BB 81000 PODGORICA ZA KCCG	(3) 02447045
	18 Ident. i nac. prevoznog sredstva u odjeluziprijecu ST040LK	19 Kcr. 888 0
	21 Ident. i nac. državnog prevoznog sredstva kojiprištaci izvozu	

3 Oblasć	4 Ulov spec	
5 Naziv	6 Broj, akcija	7 Broj državnog
9 Lice odgovorno za carinsko postupanje		
10. vrsta robe	11. opis robe	12. država izvoza
15 Zemlja porijekla NJEMAČKA	16 Zemlja porijekla 270NJEMAČKA	
20 Uslov isporuke EXW BERLIN	22 Valuta i ukupan iznos u valuti 978 14 016 84	23 Broj isprave
25 Vrsta robe 30 Ostalo	26 Linija odjavnog saobraćaja	27 Mjesto stvaranja robe
29 Carinska isprava izdavalca	30 Mjesto robe	

31 Opis robe Ostali aparati - ostale perifer. i drugi vrsta 1 - KOLETO / Ostali aparati za slanje ili primanje glasa, slike ili drugih podataka. Ostali DONACIJA UREDAJA ZA RAZMJENU INFORMACIJA IZMEĐU BOLNICA U PROCESU INTENZIVNE NJEGE	32 Količina 1	33 Vrijednost 3517.1300	34 Sadržaj robe per 31	35 Broj robe per 174 00
44 Porezne oznake i ostale informacije (F13)(BB/28 01 2022) (O33)(03/01-11296/3) (O11)(012817) (O91)(ČL 3 SL 32/20) (F50)(ČL 3 SL 32/20) (U99)(UPL 409/22-201/1) (U99)(OSLOBODENO OD PLAĆANJA DAŽBINA ZA DONACIJU) (U99)(ODLUKOM 32/20) (V20)(700)			37 FOSTUFAR 4000	38 Količina robe 154 00

40 Isprava/prehodni dokument 38075/T/6920/22/01/174 00	41 Dopunski jedinica 1.000	42 Ostalo 14.000
--	--------------------------------------	----------------------------

47. Opcioni datumi	Vrij.	Osnovna	Stopa	Iznos	48
					48 Odlučeno plaćanje
Ukupno:					49

B DETALJI OBRAČUNA

RRP : 31838
Br. Šifera : 2

50. Glavni obveznik M.B.	51. Carinska isprava izdavalca i zemlja Zastupljen od strane: Mjesto i datum:
------------------------------------	---

52. Datum i vrijeme izdavanja
J. KONTROLA POLAZNE CARINARNICE

53. Carinska isprava izdavalca i zemlja
PELAT

**Ракочевић Сања
20244**



Mališić Igor
183/Šef Spec
02117045 B



Crna Gora
MINISTARSTVO ZDRAVLJA
PODGORICA

Broj UPi - 409/22 - 2014

Podgorica, 21. 02. 2022 god.

Na osnovu Uredbe o Vladi Crne Gore ("Službeni list CG" br.80/08, 14/17 i 28/18) i Odluke o načinu ostvarivanja prava na oslobađanje od plaćanja poreza na dodatu vrijednost i carine na medicinska sredstva i zaštitnu opremu koja se uvoze kao donacija, radi suzbijanja posljedica nastalih usljed epidemije zarazne bolesti COVID 19 ("Službeni list CG", br.32/20 i br.11/21), Ministarstvo zdravlja izdaje

POTVRDU

Da se donacija Robert Koch Institute iz Njemačke u 1 sistema za prenos informacija InTouch Lite 3 u okviru projekta u borbi protiv CoVid 19, koja je usmjerena na Klinički centar Crne Gore Crne Gore, u vrijednosti Eur 14.016,84, na osnovu odluke Ministarstva zdravlja vodi u evidenciji o medicinskim sredstvima i zaštitnoj opremi koja se uvoze u Crnu Goru, radi suzbijanja posljedica nastalih usljed pandemije zarazne bolesti COVID 19 i oslobađa se od plaćanja poreza na dodatu vrijednost i carine.

MINISTARKA

dr.med Jelena Borovinić Bojović



Jelena Borovinić Bojović

Popunjeno na odgovornost pošiljaoca od 1 - 15 uključujući 19 + 21 + 22 Sa debelim crtama uokvireni dio mora popuniti prevoznik: 16-18+20+23
 A remplir sous la responsabilité de l'expéditeur 1 - 15 y compris les 19 + 21 + 22 Les parties encadrées de lignes grasses doivent être remplies par le transporteur: 16-18+20+23

Pošiljaoca de destinataire Expéditeur (ime, adresa, zemlja) Expéditeur (nom, adresse, pays) CB SCHENKER D.O.O. DOSITEJEVA 45 22310 ŠIMANOVOCI Republika Srbija			1 a) Zemlja: <input type="checkbox"/>	MEĐUNARODNI TOVARNI LIST LETTRE DE VOITURE INTERNATIONALE CMR 012817																																					
2 Primalac (ime, adresa, zemlja) Destinataire (nom, adresse, pays) KLINICKI CENTAR CRNE GORE LOJBLJANSKA 2B 81000 PODGORICA Republika Crna Gora			2 a) Zemlja: <input type="checkbox"/>	16 Prevoznik (ime, adresa, zemlja) Transporteur (nom, adresse, pays) 16 a) Spolj. trg. registrovani prevoznik: <input type="checkbox"/>																																					
3 Mesto isporuke (mesto, zemlja, datum) Lieu prévu pour la livraison de la marchandise (lieu, pays, date) PODGORICA / ME			3 a) km do YU: <input type="text"/>	17 Ostali prevoznici (ime, adresa, zemlja) Transporteurs successifs (nom, adresse, pays)																																					
4 Mesto i datum preuzimanja pošiljke na prevoz (mesto, zemlja) Lieu et date de la prise en charge de la marchandise (lieu, pays) ŠIMANOVOCI 18.02.2022			4 a) km do YU: <input type="text"/>	18 Primedbe i ograničenja prevoznika Réserves et observations du transporteur Vozač: Videti uputnik na zadnjem listu 3 A-C primetaka																																					
5 Priložene listine Documents annexés																																									
6 Oznaka i broj Marques et numéros	7 Broj koleta Nombre des colis	8 Vrsta ambalaže Nature de l'emballage KOLETA	9 Vrsta robe Désignation des marchandises MEDICINSKA OPREMA	10 Statistički broj No statistique <input type="text"/>	11 Bruto težina, kg Poids brut, kg <input type="text"/>	12 Zapremina Volume <input type="text"/>																																			
Razred Classe	Broj Chiffre	Slovo Lettre	ADR-B-5 <input type="text"/>																																						
Razred Classe	Broj Chiffre	Slovo Lettre	ADR-B-5 <input type="text"/>																																						
13 Uputstva pošiljaoce (za carinske i druge radnje) Instructions de l'expéditeur			19 Posebni dogovori Conventions particulières																																						
14 Odredbe o plaćanju vozarine Prescriptions d'affranchissement <input type="checkbox"/> Plaća pošiljaoc / Franco <input type="checkbox"/> Plaća primaoc / Non Franco			<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 40%;">20</th> <th style="width: 15%;">Plaća A payer par</th> <th style="width: 15%;">Pošiljka Expéditeur</th> <th style="width: 15%;">Vozna Monnaie</th> <th style="width: 15%;">Mesto Le destinataire</th> </tr> <tr> <td>Prevoznik / Frais de transport</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Snobenc / Réductions</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Dotaci / Sols</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Dodatki / Suppléments</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Ostali troškovi / Frais accessoires</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>UKUPNO / TOTAL</td> <td></td> <td></td> <td></td> <td></td> </tr> </table>				20	Plaća A payer par	Pošiljka Expéditeur	Vozna Monnaie	Mesto Le destinataire	Prevoznik / Frais de transport					Snobenc / Réductions					Dotaci / Sols					Dodatki / Suppléments					Ostali troškovi / Frais accessoires					UKUPNO / TOTAL				
20	Plaća A payer par	Pošiljka Expéditeur	Vozna Monnaie	Mesto Le destinataire																																					
Prevoznik / Frais de transport																																									
Snobenc / Réductions																																									
Dotaci / Sols																																									
Dodatki / Suppléments																																									
Ostali troškovi / Frais accessoires																																									
UKUPNO / TOTAL																																									
21 Ispostavljeno u Elaboré à			dana le	15 Povraćaj Remboursement																																					
22			23 18.02.22	24 Pošiljku preuzeo: Marchandises reçues. Mesto / dan Lieu / le																																					
Pošiljka / Expéditeur Signature et timbre de l'expéditeur			Pošiljku preuzeo: Signature et timbre du destinataire																																						

Copyright © 2012 CMR. All rights reserved. CMR is a registered trademark of the International Chamber of Commerce (ICC).

SCHENKER

SCHENKER KFT.
 Leshegy U. 30.
 2310 Szigetszentmiklós
 Magyarország
 Telefonsz: +36 1 2787 878
 Fax szám: +36 1 2787 888
 Email cím: schenker@DBSCHENKER.COM

DS

Vámeljárási megbízás visszaigazolás DEBER202085460

Címzett: Klinicki Centar Crne Gore Dr. Ljiljana Radulovic Ljubljanska bb 81000 Podgorica Montenegro Kontakt: Dr. Ljiljana Radulovic	Hiv. (KCCG)	Dátum: Oldal: Kontakt: Funkció: Telefonsz: Fax szám: Email cím:	2022-02-08 1 / 1 Melinda Novinszky Melinda Novinszky +36 1 2787240 Melinda.Novinszky@dbschenker.com
---	----------------	---	--

Feladó: Robert-Koch-Institut Zentrum für Internationalen Nordufer 20 13353 Berlin Németország Kontakt:	Hiv. Robert-Koch-Institut ...	Címzett: Klinicki Centar Crne Gore (KCCG) Dr. Ljiljana Radulovic Ljubljanska bb 81000 Podgorica Montenegro Kontakt: Dr. Ljiljana Radulovic	Hiv.
--	----------------------------------	--	------

Felvétel helye: GROHMANN LOGISTIK GMBH NUESSLERSTR. 30 13088 Berlin Németország Kontakt:	Hiv.	Lerakóhely: Klinicki Centar Crne Gore (KCCG) Dr. Ljiljana Radulovic Ljubljanska bb 81000 Podgorica Montenegro Kontakt: Dr. Ljiljana Radulovic	Hiv.
--	------	---	------

T&T szám:	DEBER202085460	Közlekedési biztosítás:	Szám
TO szám:	34800003704310	Vevő felvétele:	Szám
Felvétel dátuma:	2022-02-04 10:01 és 15:00 óra között	Kézbesítés az ügyfélnek:	Szám
Kiszállítás dátuma:		Háztól házig	Szám
Áruérték:	14.016,84 EUR	Veszélyes áru:	Szám
Termék neve:	DB SCHENKERsystem	Utánvétes fizetés:	Szám
Vámkezelés:	Szám		
Paritás:	DAP - Leszállítva megn.helyig		

Jelölések	Paletta típus / db	Csom. típ. és db	Árueleírás	Súly
ANG998404		1 Colli	Teldoc-Telemedizinger t	174,00 KG
Összesen:	1 Colli	1,360 CBM	0,00 LDM	174,00 KG
Méret	Szám	Hosszúság	Szélesség: Magasság	Térfogat
	0	1,13	0,61 1,99	0,000

A fenti áruk megfelelő átvételének megerősítése.

Egyéb instrukciók:
 contact consignee '+38269091714 Dr. Ljiljana Radulovic Kd-Nr. angefordert

Tevékenységünk a Magyar Szállítványozási és Logisztikai Szolgáltatók Szövetségé által kibocsátott Magyar Államközi Szállítványozási Fejeletelen (lásd www.szallitmanyozas.hu) adatai, Minden létező szállítványozási szerződésre a magyar anyagi jog az alkalmazandó. A jelen visszaigazolás, valamint a visszaigazolás alapján létrejött szállítványozási szerződésről kapcsolatos valamennyi jogvitára a magyar bíróságok kizárólagos illetékességűek. A szállítványozó a megbízás teljesítéséhez más vállalkozó szolgáltatókat (közvetített szolgáltatókat) is igénybe vehet. A dokumentum a TANGO / STAR programmal készült. Adószám: 10966925-2-44

Nemzetközi fuvarlevél (CMR)



Fuvarlevél szám: / Tour Number: S4BUDBEG0769383 RSBEGB12022-02-09

10 FEB '22 8:22

1 Feladó (Név, cím, ország) / Sender (Name, Address, Country) SCHENKER KFT. Leshegy U. 30. 2310 Szigetszentmiklos, HU		Nemzetközi fuvarlevél (CMR) International Consignment Note (CMR) Megrendelés szám / Order Number _____ Plombák: / Seals:	
2 Átvevő (Név, cím, ország) / Consignee (Name, Address, Country) SCHENKER D.O.O. Dositejeva 45 22310 Simanovci, RS		16 Fuvarozó (Név, cím, ország) / Carrier (Name, Address, Country) SCHENKER D.O.O. Dositejeva 45 22310 Simanovci, RS	
3 Áru kiszolgáltatási helye / Place of delivery of the goods 22310 Simanovci, RS		17 További fuvarozók / Successive carriers	
4 Az áru átvétel helye és dátuma / Place and date of taking over the goods 2310 Szigetszentmiklos, HU 2022-02-09		18 A fuvarozó fenntartásai és bejegyzései / Carrier's reservations and observations	
5 Mellékelt okmányok / Annexed documents Rakodási lista, Vámpapírok, ADR fuvarokmány			
6 Jelölések és számok / Marks & Nos	7 Csomagdarabszám / Csomagdarabszám	8 Csomagolás módja / Method of	9 Áruleírás / Nature of goods
	74	Colli	Rakodási lista
10 Statisztikai szám / Statistical	11 Bruttó súly (kg) / Gross weight kg	12 Térfogat (m3) / Volume m3	
	10591.488	0	
13 Feladó instrukciói / Sender's instructions Veszélyes áru az ADR fuvarokmány szerint			
15 Fuvardíjkifizetési rendelkezések / Directions as to freight payment			
20 Különleges megállapodások / Special agreements			
Raklapok / PALLETS			
Feladó / Sender	Darabok / Pieces	Átvevő / Consignee	Darabok / Pieces
Euro-raklap / Euro-pallet		Euro-raklap / Euro-pallet	
Doboz / Box		Doboz / Box	
cserélt / changed		cserélt / changed	
nem cserélt / not changed		nem cserélt / not changed	
Feladó aláírása / Signature sender	Átvevő aláírása / Signature consignee		
21 Kiállítás helye / Established in Szigetszentmiklos időpontja / on 2022-02-09		24 Az áru átvétele / Goods received	
22 SCHENKER KFT. Leshegy U. 30. 2310 Szigetszentmiklos		23 DOO "TRANSPORT BERAR" VUJICE VUJANOVA 285 SRB 23270 Melenci 80 +381 23 731 329	
A feladó aláírása és bélyegzője / Signature and stamp of sender		A fuvarozó aláírása és bélyegzője / Signature and stamp of carrier	
25 Részletek a távolsági kalkulációhoz / Details for calculation of distance details		Fuvardíj kalkulációja / Calculation of transport price	
From	to	Díjszámítási súly (kg) Tarifa Áru típusa Deviza Díjszámítási egység Fuvardíj Charg.Wt.Kg Tariff Goods Type Curr. Chrg.Item Trans.price	
	km km		
27 Rendszámok Pótkocsi / License plates Tractor/ Trailer/SWAP Vontató ZR086DI		Rakomány / Load capacity in kg	
		Összeg / Sum	

EUROPEISCHE GEMEINSCHAFT

K.C.C.G.

LISTE DER WARENPOSITIONEN - AUSFUHR

MRN 22DE210171000174E3



Vordrucke (3)

2 2

Pos.- Nr. (32)	Anzahl und Art der Packstücke, Zeichen und Nummern der Packstücke (31.1)	Warenbezeichnung (31.4)
	Versender/Ausführer (2)	Empfänger (8)
	Kennzeichen des Beförderungsmittels beim Abgang (18)	Warennummer (33)
	Kennnummer der Sendung (Unique Consignment Ref. Nr.) (7)	Summarische Anmeldung/Vorpapier (40)
	Vorgelegte Unterlagen / Bescheinigungen (44.1)	Container-Nr. (31.3) Nummer des Zollverschlusses (S26)
	Besondere Vermerke (44.2)	Verfahren (37) Ausfuhrland (15a) Bestimmungs- (17a) Rohmasse (kg) (35)
UNDG (44.4)	Beförderungskosten, Code für die Zahlungsweise (S29)	Anmeldungsart (1) Statistischer Wert (46) Eigenmasse (kg) (38)
1	1. 1 PK, Packung/Packstück	andere Send- oder Empfangsgeräte für Töne, Bilder oder andere Daten, hier: 1x Telemedizingerät "InTouch Lite 3 Factory Refurbished / 20-20310"
	DE3580105 ROBERT KOCH INSTITUT Nordufer 20 13353 Berlin (DE) Deutschland	85171800
		ohne
	Internationale Unterlagen: TN325 R:ZIC 1_01/2022 Proformarechnung T:Y901 R: nicht von der Liste der Güter mit doppeltem Verwendungszweck (Anhang I der Dual-use-VO) erfasste Güter	
		1000 DE ME 174
		160

Letter of Intent

to

implement the joint cooperation project
"COVID-19 Response and Recovery Alliance for
Montenegro and the Western Balkans – CORRAL"

between

1. the Federal Republic of Germany, represented by the German Federal Ministry of Health,
represented by the President of the **Robert Koch Institute ("RKI")**, Nordufer 20, 13353 Berlin,
Germany,

and

2. the **Charité – Universitätsmedizin Berlin**, Department of Anesthesiology, represented by the
Deputy Medical Director of the Charité, Augustenburger Platz 1, 13353 Berlin, Germany,

and

3. the **Clinical Centre of Montenegro ("KCCG")**, represented by the Director of the KCCG, Ljubljanska
bb, 81000 Podgorica, Montenegro

and

4. the **WHO Country Office Montenegro ("WHO Montenegro")**, represented by the Head of WHO
Country Office, Serdara Jola Piletica br. 8, 81000 Podgorica, Montenegro

and

5. the **Institute of Public Health of Montenegro ("IPH")**, represented by the Director of the IPH, Džona
Džeksona bb, 81000 Podgorica, Montenegro

hereinafter, jointly or individually, referred to as "Partner" or "Partners".

Preamble

Already before, the COVID-19-pandemic, RKI has been active in Montenegro. Additionally, it conducted an in-depth intra action review in Montenegro during the pandemic. Based on the results of the intra action review, several needs were identified in the main areas of immediate response to COVID-19, but also to future threats. The good relationship between RKI and its long-term cooperation partner Charité with the **Government of Montenegro with its IPH and WHO Montenegro** provides an excellent opportunity to address these needs first in Montenegro, with the possibility to subsequently expand the subprojects to other WB6, with Montenegro acting as a hub.

In the light of this, the Partners intend to implement the joint cooperation project "**COVID-19 Response and Recovery Alliance for Montenegro and the Western Balkans**" (hereinafter referred to as "**CORRAL**"). **CORRAL** aims to support current response activities by establishing capacities that will likewise increase resilience to future threats, in particular, by means of implementing the four subprojects

- "**Western Balkan Laboratory Network (WALTON)**",
- "**Montenegro COVID-19 Clinical Associates Initiative (MoCCA)**",
- "**MONTENEGRO VIRTUAL Emergency Operation Center (MovE)**" and
- "**Field Epidemiology Training Programme (FETP-WB)**"

The first sub-project to be established, namely, **MOCCA**, aims to support a unified approach to the treatment of patients with COVID-19 and other severe diseases in **KCCG** by establishing of a network of clinical companions. It reflects the outcomes of two consecutive visits to Montenegro, and in-depths discussions between colleagues from **KCCG** and experts from the **Charité** and **RKI**. **MoCCA** will address clinical experts in the field of COVID-19 treatment, and ICU experts in general enabling a mutual exchange of experience and knowledge between **KCCG** and **Charité**.

Declaration of Intent

The Partners agree that this Letter of Intent is neither intended to be legally binding nor to confer any legal rights or commitments nor to impose any financial or commercial responsibilities on any of the Partners. Such provisions and specifications are subject to separate cooperation agreements in writing to be duly signed by the legal representatives of the Partners.

Considering this, the Partners nonetheless express their serious intention to implement **CORRAL** in accordance with their commonly defined project goals.

For KCCG

Dr Ljiljana Radulović,
Director of Clinical Centre of Montenegro

Signature: 

Podgorica, 24 September 2021

For IPH

Dr Igor Galić
Head of Institute of Public Health
Montenegro

Signature: 

Podgorica, 24 September 2021

For RKI

Dr Andreas Jansen, Deputy Head of Centre
for International Health Protection,
on behalf of President of the Robert Koch
Institute, Prof. Dr Lothar H. Wieler

Signature: 

Podgorica, 24 September 2021

For Charité

Dr Joachim Seybold,
Deputy Medical Director of
Charité – Universitätsmedizin Berlin

Signature: 

Podgorica, 24 September 2021

JZU KLINIČKI CENTAR CRNE GORE

Skladište: Glavni magacin KCCG:Prijemnice-OSSIT

Prijemnica br. WH/IN/23/00155

Dobavljač: **Savezna Republika Njemačka koju predstavlja Njemačko ministarstvo zdravlja.** Datum: **23.03.2023**
Narudžba: **P15301** Status: **Gotovo**
Otpremnica:
Faktura: **Ugovor o Saradnji (Donaciji) Projekat br.1368-1968 (D81968) od 08.12.2021**

Broj	Artikal	Seriya	Rok	Količina	J.mj.	Cijena	Iznos
1	[R-12043] Portabilni ultrazvučni aparat			2	kom.	5.750,0000	11.500,0000
2	[R-12044] Robot za telemedicinu			1	kom.	35.000,0000	35.000,0000
Ukupan iznos:							46.500,0000 €

Kontrolu izvršio:



potpis

Napomena:

Ažurirao: **Abdić Kenan**
Ovjerio: **Abdić Kenan**

27.03.2023 10:37
23.03.2023 10:23

Preuzeo:

23.03 2023

REVERS br. 72

Potvrđujem da sam primio iz ekonomata na upotrebu za

Interna klinika - Intezivna jedinica

sledeće

Sanja Janović

Red. broj	Količina	NAIMENOVANJE	Cijena	Iznos
		01. 1 kom. Robot za telemedicinu		76635

Izdala, A. Keran

Odobrava,

Primio, Janović Sanja

29. 03 2023

REVERS br. 77

Potvrđujem da sam primio iz ekonomata na upotrebu za

Odj. Centralne intezivne terapije

Jelena Božović

sljedeće

Red. broj	Količina	NAIMENOVANJE	Cijena	Iznos
01.	1 kom.	Portabilni ULTRAZVUK		76641

Izdac: A. Kerner

Odobrava,

Primio: Jelena Božović

21. 03 2023

REVERS br. 65

Potvrđujem da sam primio iz ekonomata na upotrebu za

Kliniku za Neurologiju

Bogovac Sladja

sledeće

Red. broj	Količina	NAIMENOVANJE	Cijena	Iznos
		<u>Ol. 1kcm. Portabilni ultrazvok</u>		<u>76617</u>

Izdavao
A. Kenan

Odobrava,

Primio,
Megara